Dashboard
Manage Tickers

LIVN LivaNova PLC

Nasdaq livanova.com


$ 53.73 $ -0.16 (-0.3 %)    

Friday, 17-Oct-2025 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 53.73
$ 53.94
$ 41.92 x 50
$ 59.56 x 3
$ 53.61 - $ 54.29
$ 32.48 - $ 58.91
405,823
na
2.93B
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 02-25-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 08-01-2024 06-30-2024 10-Q
6 05-03-2024 03-31-2024 10-Q
7 02-29-2024 12-31-2023 10-K
8 11-01-2023 09-30-2023 10-Q
9 07-26-2023 06-30-2023 10-Q
10 05-03-2023 03-31-2023 10-Q
11 02-27-2023 12-31-2022 10-K
12 11-02-2022 09-30-2022 10-Q
13 08-03-2022 06-30-2022 10-Q
14 05-04-2022 03-31-2022 10-Q
15 03-01-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 07-28-2021 06-30-2021 10-Q
18 04-28-2021 03-31-2021 10-Q
19 03-01-2021 12-31-2020 10-K
20 10-29-2020 09-30-2020 10-Q
21 07-29-2020 06-30-2020 10-Q
22 04-30-2020 03-31-2020 10-Q
23 03-02-2020 12-31-2019 10-K
24 10-30-2019 09-30-2019 10-Q
25 07-31-2019 06-30-2019 10-Q
26 05-01-2019 03-31-2019 10-Q
27 03-18-2019 12-31-2018 10-K
28 11-01-2018 09-30-2018 10-Q
29 08-02-2018 06-30-2018 10-Q
30 05-03-2018 03-31-2018 10-Q
31 02-28-2018 12-31-2017 10-K
32 11-02-2017 09-30-2017 10-Q
33 08-09-2017 06-30-2017 10-Q
34 05-03-2017 03-31-2017 10-Q
35 03-01-2017 12-31-2016 10-K
36 11-02-2016 09-30-2016 10-Q
37 08-05-2016 06-30-2016 10-Q
38 05-09-2016 03-31-2016 10-Q
39 12-02-2015 10-18-2015 10-Q
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

needham-reiterates-buy-on-livanova-maintains-64-price-target
Needham Reiterates Buy on LivaNova, Mainta...
09/03/2025 11:58:42

Needham analyst Mike Matson reiterates LivaNova (NASDAQ:LIVN) with a Buy and maintains $64 price target.

barclays-maintains-equal-weight-on-livanova-raises-price-target-to-58
Barclays Maintains Equal-Weight on LivaNov...
08/21/2025 14:45:28

Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and raises the price target from $55 to $58.

shopify-astera-labs-myriad-genetics-grocery-outlet-and-other-big-stocks-moving-higher-on-wednesday
Shopify, Astera Labs, Myriad Genetics, Gro...
08/06/2025 14:42:13

livanova-raises-fy2025-adj-eps-guidance-from-360-370-to-370-380-vs-365-est-raises-fy2025-sales-guidance-from-1316b-1341b-to-1353b-1366b-vs-1328b-est
LivaNova Raises FY2025 Adj EPS Guidance fr...
08/06/2025 10:02:39

LivaNova (NASDAQ:LIVN) raises FY2025 Adj EPS guidance from $3.60-$3.70 to $3.70-$3.80 vs $3.65 analyst estimate. Raises FY2025 ...

livanova-q2-adj-eps-105-beats-086-estimate-sales-352500m-beat-332269m-estimate
LivaNova Q2 Adj. EPS $1.05 Beats $0.86 Est...
08/06/2025 10:00:37

LivaNova (NASDAQ:LIVN) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $0.86 by 22....

Core News & Articles
Earnings Scheduled For August 6, 2025
08/06/2025 08:33:21

livenova-completes-core-vns-study-evaluating-outcomes-of-real-world-evidence-for-more-than-800-people-with-epilepsy-treated-with-vns-therapy
LiveNova Completes CORE-VNS Study Evaluati...
06/05/2025 12:17:55

Long-term, real-world evidence demonstrates early and lasting outcomes of adjunctive VNS Therapy on severe focal seizures

livanova-publishes-24-month-data-on-generalized-tonic-clonic-seizures-in-people-with-dre-from-core-vns-three-year-study-in-epilepsia
LivaNova Publishes 24-Month Data On Genera...
06/05/2025 12:04:00

This is the latest prospective evaluation of VNS Therapy in generalized tonic-clonic seizuresFindings include 77% median seizur...

livanova-initiates-process-with-us-cms-to-seek-reconsideration-of-national-medicare-coverage-for-vns-therapy-in-unipolar-patients-with-treatment-resistant-depression
LivaNova Initiates Process With U.S. CMS T...
06/04/2025 12:12:18

Final critical papers on RECOVER clinical study data accepted, supporting the Company's submission for coverage reconsidera...

wolfe-research-upgrades-livanova-to-outperform-announces-60-price-target
Wolfe Research Upgrades LivaNova to Outper...
05/20/2025 16:15:27

Wolfe Research analyst Mike Polark upgrades LivaNova (NASDAQ:LIVN) from Peer Perform to Outperform and announces $60 price t...

needham-reiterates-buy-on-livanova-maintains-64-price-target
Needham Reiterates Buy on LivaNova, Mainta...
05/13/2025 12:00:07

Needham analyst Mike Matson reiterates LivaNova (NASDAQ:LIVN) with a Buy and maintains $64 price target.

barclays-maintains-equal-weight-on-livanova-lowers-price-target-to-55
Barclays Maintains Equal-Weight on LivaNov...
05/08/2025 16:39:03

Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and lowers the price target from $56 to $55.

baird-maintains-outperform-on-livanova-raises-price-target-to-61
Baird Maintains Outperform on LivaNova, Ra...
05/08/2025 12:44:38

Baird analyst David Rescott maintains LivaNova (NASDAQ:LIVN) with a Outperform and raises the price target from $55 to $61.

livanova-updates-fy2025-adj-eps-guidance-from-365-375-to-360-370-vs-356-est-updates-fy2025-sales-guidance-from-130b-130b-to-132b-134b-on-a-reported-basis-vs-130b-est
LivaNova Updates FY2025 Adj EPS Guidance f...
05/07/2025 10:23:58

livanova-updates-fy2025-adj-eps-guidance-from-365-375-to-360-370-vs-356-est
LivaNova Updates FY2025 Adj EPS Guidance f...
05/07/2025 10:02:50

Adjusted diluted earnings per share for 2025 is now expected to be in the range of $3.60 to $3.70 (versus $3.65 to $3.75 prior,...

livanova-q1-adj-eps-088-beats-076-estimate-sales-31690m-beat-30234m-estimate
LivaNova Q1 Adj. EPS $0.88 Beats $0.76 Est...
05/07/2025 10:01:41

livanova-announced-12-month-top-line-data-from-its-osprey-randomized-controlled-trial-evaluating-outcomes-with-the-aura6000-system-for-the-treatment-of-moderate-to-severe-obstructive-sleep-apnea
LivaNova Announced 12-month, Top-line Data...
05/07/2025 09:49:37

Core News & Articles
Earnings Scheduled For May 7, 2025
05/07/2025 08:33:08

needham-reiterates-buy-on-livanova-maintains-64-price-target
Needham Reiterates Buy on LivaNova, Mainta...
03/17/2025 12:51:48

Needham analyst Mike Matson reiterates LivaNova (NASDAQ:LIVN) with a Buy and maintains $64 price target.

barclays-maintains-equal-weight-on-livanova-lowers-price-target-to-56
Barclays Maintains Equal-Weight on LivaNov...
03/07/2025 11:24:41

Barclays analyst Matt Miksic maintains LivaNova (NASDAQ:LIVN) with a Equal-Weight and lowers the price target from $58 to $56.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION